The role and impact of quantitative discovery pathology
Steven J Potts1, G David Young, Frank A Voelker
1Flagship Biosciences, Flagstaff, AZ, United States. steve@flagshipbio.com
Abstract:
The decision to advance an early-stage compound into formal preclinical testing depends on confidence in mechanism, efficacy and toxicity profiles. A substantial percentage of this confidence comes from histopathology interpretation, as the local tissue environment contains strong signals of both efficacy and toxicity. Accessing this tissue information is made difficult by biological variability across organs and tissues, an insufficient pool of pathology experts working in discovery, and the high subjectivity and individual isolation of microscope-based observations. This article describes how whole-slide imaging and quantitative analysis by trained pathologists are improving early-stage decision-making.
More Related Videos
08:40Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Related Concept Videos
Drug Discovery: Overview
Pharmacogenomics: Identification of New Drug Targets
Steps in Outbreak Investigation
Biostatistics: Overview
Discrete variables are...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
